Quashing the resistance: MicroRNA regulates drug tolerance in subset of lung cancers

lung cancer
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia

Relapse of disease following conventional treatments remains one of the central problems in cancer management, yet few therapeutic agents targeting drug resistance and tolerance exist. New research conducted at the Cancer Center at Beth Israel Deaconess Medical Center found that a microRNA—a small fragment of non-coding genetic material that regulates gene expression—mediates drug tolerance in lung cancers with a specific mutation. The findings, published today in Nature Metabolism, suggest that the microRNA could serve as a potential target for reversing and preventing drug tolerance in a subset of non-small-cell lung cancers.

"These results were a surprise and represent a total novel finding in the area," said senior author Frank J. Slack, Ph.D., Director of the HMS Initiative for RNA Medicine at the Cancer Center at BIDMC. "We have identified a novel pathway required for that is regulated by a microRNA. Targeting this microRNA reduces tolerance, suggesting a potential new approach for treatment of lung cancer."

Lung cancer is the leading causes of cancer-related deaths among both men and women. As a class, non-small cell lung cancers—which comprise about 85 percent of lung cancer diagnoses—tend to be less aggressive but harder to treat than small cell lung cancers. About one in 10 non-small-cell lung carcinomas carries a mutation to a protein called EGFR on the surface of the cancer's cells.

Since 2003, several medications that block the activity of the EGFR protein—a class of drugs called —have received FDA-approval for the treatment of EGFR-positive lung cancers. However, despite patients' sometimes dramatic initial response to these medications, many patients eventually relapse as their cancer develops resistance to the treatment. By studying drug resistant tumor cells, Slack and colleagues identified the key players driving the development of .

"In this study, we discovered that a microRNA known as miR-147b is a critical mediator of resistance among a subpopulation of tumor cells that adopt a tolerance strategy to defend against EGFR-based anticancer treatments," said Slack, who is also the Shields Warren Mallinckrodt Professor of Medical Research, Departments of Pathology and Medicine, Harvard Medical School. "We are currently testing the idea of targeting this new pathway as a therapy in clinically relevant mouse models of EGFR-mutant lung ."


Explore further

Origin of resistance to lung-cancer drug discovered

More information: miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma, Nature Metabolism (2019). DOI: 10.1038/s42255-019-0052-9 , https://www.nature.com/articles/s42255-019-0052-9
Journal information: Nature Metabolism

Citation: Quashing the resistance: MicroRNA regulates drug tolerance in subset of lung cancers (2019, April 8) retrieved 19 June 2019 from https://medicalxpress.com/news/2019-04-quashing-resistance-microrna-drug-tolerance.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
91 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more